Bette T Korber

List of Publications by Year
in descending order

270 papers	41,366 citations	1994 101 h-index	2828 191 g-index
297 all docs	297 docs citations	297 times ranked	28179 citing authors

#	Article	IF	Citations
1	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 2022, 386, 1088-1091.	27.0	338
2	Structural diversity of the SARS-CoV-2 Omicron spike. Molecular Cell, 2022, 82, 2050-2068.e6.	9.7	125
3	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	27.8	117
4	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Reports, 2022, 38, 110514.	6.4	23
5	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nature Medicine, 2022, 28, 1288-1296.	30.7	44
6	Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. Science Translational Medicine, 2022, 14, eabm4908.	12.4	21
7	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host and Microbe, 2021, 29, 23-31.e4.	11.0	308
8	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science, 2021, 371, .	12.6	49
9	Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus. Nature Communications, 2021, 12, 1203.	12.8	14
10	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host and Microbe, 2021, 29, 529-539.e3.	11.0	324
11	The SARS-CoV-2 Spike variant D614G favors an open conformational state. Science Advances, 2021, 7, .	10.3	156
12	Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2. Viruses, 2021, 13, 927.	3.3	29
13	SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. Nature Microbiology, 2021, 6, 821-823.	13.3	221
14	Effect of epitope variant co-delivery on the depth of CD8 TÂcell responses induced by HIV-1 conserved mosaic vaccines. Molecular Therapy - Methods and Clinical Development, 2021, 21, 741-753.	4.1	9
15	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Science, 2021, 373, .	12.6	318
16	Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. New England Journal of Medicine, 2021, 384, 2352-2354.	27.0	202
17	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. PLoS Pathogens, 2021, 17, e1009624.	4.7	2
18	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Cell Host and Microbe, 2021, 29, 1093-1110.	11.0	73

#	Article	IF	Citations
19	Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. EBioMedicine, 2021, 63, 103175.	6.1	10
20	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nature Medicine, 2021, 27, 1718-1724.	30.7	39
21	Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens. PLoS Pathogens, 2021, 17, e1009807.	4.7	13
22	Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. Journal of Clinical Investigation, 2021, 131, .	8.2	6
23	T cell-based strategies for HIV-1 vaccines. Human Vaccines and Immunotherapeutics, 2020, 16, 713-722.	3.3	39
24	Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth. Vaccines, 2020, 8, 360.	4.4	12
25	Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies. Current Opinion in HIV and AIDS, 2020, 15, 267-274.	3.8	22
26	Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail. IScience, 2020, 23, 101836.	4.1	11
27	Emergence of SARS-CoV-2 through recombination and strong purifying selection. Science Advances, 2020, 6, .	10.3	307
28	Estimating the Timing of Early Simian-Human Immunodeficiency Virus Infections: a Comparison between Poisson Fitter and BEAST. MBio, 2020, 11, .	4.1	6
29	Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell, 2020, 182, 812-827.e19.	28.9	3,551
30	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Annual Review of Immunology, 2020, 38, 673-703.	21.8	74
31	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nature Communications, 2019, 10, 2898.	12.8	35
32	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008026.	4.7	56
33	Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine. PLoS Pathogens, 2019, 15, e1007564.	4.7	20
34	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host and Microbe, 2019, 25, 59-72.e8.	11.0	124
35	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. Journal of Virology, 2018, 92, .	3.4	46
36	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. Journal of Infectious Diseases, 2018, 218, 633-644.	4.0	35

#	Article	IF	Citations
37	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of Virology, 2018, 92, .	3.4	10
38	Graphâ€based optimization of epitope coverage for vaccine antigen design. Statistics in Medicine, 2018, 37, 181-194.	1.6	18
39	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. Cell Reports, 2018, 25, 893-908.e7.	6.4	91
40	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nature Communications, 2018, 9, 1928.	12.8	83
41	A single, continuous metric to define tiered serum neutralization potency against HIV. ELife, 2018, 7, .	6.0	16
42	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet, The, 2018, 392, 232-243.	13.7	269
43	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. Journal of Experimental Medicine, 2018, 215, 1571-1588.	8.5	366
44	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	28.9	173
45	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathogens, 2018, 14, e1006860.	4.7	68
46	Polyvalent vaccine approaches to combat <scp>HIV</scp>â€1 diversity. Immunological Reviews, 2017, 275, 230-244.	6.0	46
47	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. Science Immunology, 2017, 2, .	11.9	119
48	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Reports, 2017, 18, 2175-2188.	6.4	69
49	Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4477-4482.	7.1	18
50	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nature Communications, 2017, 8, 15711.	12.8	137
51	Staged induction of HIV-1 glycanâ€œdependent broadly neutralizing antibodies. Science Translational Medicine, 2017, 9, .	12.4	212
52	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. AIDS Research and Human Retroviruses, 2017, 33, 859-868.	1.1	18
53	Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins. Journal of Virology, 2017, 91, .	3.4	23
54	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Translational Medicine, 2017, 9, .	12.4	106

#	Article	IF	Citations
55	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Science Translational Medicine, 2017, 9, .	12.4	87
56	Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. Journal of Virology, 2017, 91, .	3.4	23
57	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. PLoS Pathogens, 2017, 13, e1006510.	4.7	63
58	A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance. Frontiers in Immunology, 2016, 7, 162.	4.8	24
59	Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein. PLoS Computational Biology, 2016, 12, e1005094.	3.2	17
60	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathogens, 2016, 12, e1005520.	4.7	150
61	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell, 2016, 165, 813-826.	28.9	379
62	Defining the HLA class Iâ€associated viral antigen repertoire from HIVâ€1â€infected human cells. European Journal of Immunology, 2016, 46, 60-69.	2.9	57
63	Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine. Scientific Reports, 2016, 6, 33987.	3.3	35
64	Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8 + T Cells. MBio, 2016, 7, .	4.1	16
65	Integrated sequence and immunology filovirus database at Los Alamos. Database: the Journal of Biological Databases and Curation, 2016, 2016, baw047.	3.0	3
66	Broadly targeted CD8 ⁺ T cell responses restricted by major histocompatibility complex E. Science, 2016, 351, 714-720.	12.6	260
67	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Molecular Therapy, 2016, 24, 832-842.	8.2	107
68	HIV-Host Interactions: Implications for Vaccine Design. Cell Host and Microbe, 2016, 19, 292-303.	11.0	143
69	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. Cell, 2016, 165, 449-463.	28.9	305
70	Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. Molecular Therapy, 2016, 24, 375-384.	8.2	35
71	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathogens, 2016, 12, e1005742.	4.7	81
72	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. Viruses, 2015, 7, 5443-5475.	3.3	26

#	Article	IF	Citations
73	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens, 2015, 11, e1005042.	4.7	145
74	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. Journal of Virology, 2015, 89, 6462-6480.	3.4	40
75	Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. Journal of Immunological Methods, 2015, 416, 105-123.	1.4	37
76	Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. Journal of Virology, 2015, 89, 2659-2671.	3.4	123
77	CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Research, 2015, 43, W213-W219.	14.5	118
78	Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors. Journal of Virology, 2015, 89, 1512-1522.	3.4	47
79	A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. Journal of Virology, 2015, 89, 2507-2519.	3.4	42
80	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. Journal of Virology, 2015, 89, 8643-8650.	3.4	42
81	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	11.0	66
82	Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected. Journal of Infectious Diseases, 2015, 211, 936-946.	4.0	18
83	Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer. Journal of Virology, 2014, 88, 9538-9552.	3.4	30
84	Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection. AIDS Research and Human Retroviruses, 2014, 30, A58-A58.	1.1	2
85	Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. Retrovirology, 2014, 11, 69.	2.0	27
86	Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. Vaccine, 2014, 32, 3995-4000.	3.8	4
87	Fitness costs of rifampicin resistance in <scp><i>M</i></scp><i>ycobacterium tuberculosis</i> are amplified under conditions of nutrient starvation and compensated by mutation in the Î²â€² subunit of <scp>RNA</scp> polymerase. Molecular Microbiology, 2014, 91, 1106-1119.	2.5	85
88	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature, 2014, 505, 502-508.	27.8	140
89	Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. Journal of Virology, 2014, 88, 2489-2507.	3.4	274
90	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell, 2014, 158, 481-491.	28.9	266

#	Article	IF	Citations
91	Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies. Journal of Virology, 2014, 88, 12623-12643.	3.4	75
92	Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors. Journal of Experimental Medicine, 2014, 211, 1273-1280.	8.5	76
93	Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. Aids, 2014, 28, 163-169.	2.2	334
94	Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design. Journal of Virology, 2013, 87, 7218-7233.	3.4	119
95	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. Cell, 2013, 155, 531-539.	28.9	334
96	A multiple-alignment based primer design algorithm for genetically highly variable DNA targets. BMC Bioinformatics, 2013, 14, 255.	2.6	41
97	A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. Journal of Immunological Methods, 2013, 395, 1-13.	1.4	19
98	Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1. Journal of Virology, 2013, 87, 4185-4201.	3.4	83
99	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013, 496, 469-476.	27.8	961
100	Modeling sequence evolution in HIV-1 infection with recombination. Journal of Theoretical Biology, 2013, 329, 82-93.	1.7	9
101	A Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope Glycoprotein. PLoS Computational Biology, 2013, 9, e1003046.	3.2	53
102	Hepatitis C Genotype 1 Mosaic Vaccines Are Immunogenic in Mice and Induce Stronger T-Cell Responses than Natural Strains. Vaccine Journal, 2013, 20, 302-305.	3.1	19
103	Phenotypic properties of transmitted founder HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6626-6633.	7.1	379
104	Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial. PLoS ONE, 2013, 8, e53629.	2.5	165
105	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. PLoS ONE, 2013, 8, e75665.	2.5	214
106	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. Journal of Clinical Investigation, 2013, 123, 380-93.	8.2	165
107	Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate. PLoS Pathogens, 2012, 8, e1002881.	4.7	139
108	Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape. PLoS Pathogens, 2012, 8, e1002721.	4.7	159

#	Article	IF	Citations
109	Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing. PLoS Pathogens, 2012, 8, e1002880.	4.7	74
110	Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys. Journal of Virology, 2012, 86, 11434-11440.	3.4	42
111	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Research and Human Retroviruses, 2012, 28, 1444-1457.	1.1	191
112	Distinct Evolutionary Pressures Underlie Diversity in Simian Immunodeficiency Virus and Human Immunodeficiency Virus Lineages. Journal of Virology, 2012, 86, 13217-13231.	3.4	30
113	Designing and Testing Broadly-Protective Filoviral Vaccines Optimized for Cytotoxic T-Lymphocyte Epitope Coverage. PLoS ONE, 2012, 7, e44769.	2.5	20
114	Mycobacterium tuberculosis â€" Heterogeneity revealed through whole genome sequencing. Tuberculosis, 2012, 92, 194-201.	1.9	75
115	Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology, 2012, 428, 121-127.	2.4	46
116	Network Analysis of the Communication Pathways in HIV-1 Envelope Proteins For Mechanistic Understanding of Immune Escape. Biophysical Journal, 2011, 100, 227a-228a.	0.5	0
117	Mapping HIV-1 Vaccine Induced T-Cell Responses: Bias towards Less-Conserved Regions and Potential Impact on Vaccine Efficacy in the Step Study. PLoS ONE, 2011, 6, e20479.	2.5	61
118	Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. Virology, 2011, 409, 163-174.	2.4	18
119	Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine, 2011, 9, 208.	4.4	143
120	Building on the past to define an efficient path to an HIV vaccine. Expert Review of Vaccines, 2011, 10, 929-931.	4.4	3
121	Converging on an HIV Vaccine. Science, 2011, 333, 1589-1590.	12.6	17
122	The <i>TRIM5</i> Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys. Journal of Virology, 2011, 85, 10389-10398.	3.4	43
123	Epitope-Specific CD8⁺T Lymphocytes Cross-Recognize Mutant Simian Immunodeficiency Virus (SIV) Sequences but Fail To Contain Very Early Evolution and Eventual Fixation of Epitope Escape Mutations during SIV Infection. Journal of Virology, 2011, 85, 3746-3757.	3.4	32
124	Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection. Journal of Virology, 2011, 85, 10518-10528.	3.4	141
125	Vaccine-Induced CD8+ T Lymphocytes of Rhesus Monkeys Recognize Variant Forms of an HIV Epitope but Do Not Mediate Optimal Functional Activity. Journal of Immunology, 2011, 186, 5663-5674.	0.8	6
126	Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1156-63.	7.1	106

#	Article	IF	Citations
127	AIDS Research Pioneer Gerry Myers Dies. AIDS Research and Human Retroviruses, 2011, 27, 453-454.	1.1	0
128	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. PLoS Pathogens, 2011, 7, e1001273.	4.7	90
129	Genital Tract Sequestration of SIV following Acute Infection. PLoS Pathogens, 2011, 7, e1001293.	4.7	18
130	Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals. Journal of Virology, 2011, 85, 9286-9299.	3.4	24
131	Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections. PLoS Pathogens, 2011, 7, e1002209.	4.7	114
132	A Signature in HIV-1 Envelope Leader Peptide Associated with Transition from Acute to Chronic Infection Impacts Envelope Processing and Infectivity. PLoS ONE, 2011, 6, e23673.	2.5	54
133	Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics, 2010, 11, 532.	2.6	83
134	The role of recombination in the emergence of a complex and dynamic HIV epidemic. Retrovirology, 2010, 7, 25.	2.0	110
135	Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nature Medicine, 2010, 16, 324-328.	30.7	211
136	jpHMM: improving the reliability of recombination prediction in HIV-1. Nucleic Acids Research, 2010, 38, 1059-1059.	14.5	3
137	HIV classification using the coalescent theory. Bioinformatics, 2010, 26, 1409-1415.	4.1	9
138	Autologous Neutralizing Antibodies to the Transmitted/Founder Viruses Emerge Late after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys. Journal of Virology, 2010, 84, 6018-6032.	3.4	30
139	Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables. Journal of Virology, 2010, 84, 1631-1636.	3.4	304
140	Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. Journal of General Virology, 2010, 91, 1194-1206.	2.9	27
141	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathogens, 2010, 6, e1000890.	4.7	263
142	Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies. PLoS Computational Biology, 2010, 6, e1000955.	3.2	78
143	Envelope Vaccination Shapes Viral Envelope Evolution following Simian Immunodeficiency Virus Infection in Rhesus Monkeys. Journal of Virology, 2010, 84, 953-963.	3.4	10
144	Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nature Medicine, 2010, 16, 319-323.	30.7	351

#	Article	IF	Citations
145	Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies. Journal of Virology, 2010, 84, 1439-1452.	3.4	589
146	HIV-1 Vaccine Development After STEP. Annual Review of Medicine, 2010, 61, 153-167.	12.2	89
147	Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing. PLoS ONE, 2010, 5, e12303.	2.5	259
148	Rare HLA Drive Additional HIV Evolution Compared to More Frequent Alleles. AIDS Research and Human Retroviruses, 2009, 25, 297-303.	1.1	10
149	jpHMM: Improving the reliability of recombination prediction in HIV-1. Nucleic Acids Research, 2009, 37, W647-W651.	14.5	145
150	Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination. Journal of Virology, 2009, 83, 2201-2215.	3.4	61
151	T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces. Journal of Virology, 2009, 83, 8300-8314.	3.4	137
152	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1253-1272.	8.5	562
153	Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants. Journal of Virology, 2009, 83, 3556-3567.	3.4	354
154	Partial Protection of Simian Immunodeficiency Virus (SIV)-Infected Rhesus Monkeys against Superinfection with a Heterologous SIV Isolate. Journal of Virology, 2009, 83, 2686-2696.	3.4	34
155	HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC. PLoS Pathogens, 2009, 5, e1000414.	4.7	161
156	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. Journal of Experimental Medicine, 2009, 206, 1117-1134.	8.5	295
157	Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology, 2009, 385, 505-520.	2.4	78
158	Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology, 2009, 394, 91-98.	2.4	28
159	Modeling sequence evolution in acute HIV-1 infection. Journal of Theoretical Biology, 2009, 261, 341-360.	1.7	162
160	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1273-1289.	8.5	684
161	The evolutionary rate dynamically tracks changes in HIV-1 epidemics: Application of a simple method for optimizing the evolutionary rate in phylogenetic trees with longitudinal data. Epidemics, 2009, 1, 230-239.	3.0	20
162	The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Current Opinion in HIV and AIDS, 2009, 4, 408-417.	3.8	50

#	Article	IF	Citations
163	Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo. PLoS ONE, 2009, 4, e5683.	2.5	205
164	Research on infectious disease dynamics. Introduction. Epidemics, 2009, 1, 1.	3.0	0
165	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7552-7557.	7.1	1,708
166	Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing. Journal of Virology, 2008, 82, 3952-3970.	3.4	540
167	A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10489-10494.	7.1	75
168	HLA Class I-Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load. Journal of Virology, 2008, 82, 6434-6446.	3.4	126
169	Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics, 2008, 24, 1639-1640.	4.1	49
170	Targeting of a CD8 T Cell Env Epitope Presented by HLA-B*5802 Is Associated with Markers of HIV Disease Progression and Lack of Selection Pressure. AIDS Research and Human Retroviruses, 2008, 24, 72-82.	1.1	58
171	Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. Aids, 2008, 22, 447-456.	2.2	29
172	Coping with Viral Diversity in HIV Vaccine Design: A Response to Nickle et al.. PLoS Computational Biology, 2008, 4, e15.	3.2	30
173	Extensive Intrasubtype Recombination in South African Human Immunodeficiency Virus Type 1 Subtype C Infections. Journal of Virology, 2007, 81, 4492-4500.	3.4	62
174	Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1. PLoS Pathogens, 2007, 3, e94.	4.7	153
175	Increased Sequence Diversity Coverage Improves Detection of HIV-Specific T Cell Responses. Journal of Immunology, 2007, 179, 6638-6650.	0.8	32
176	Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations. Science, 2007, 315, 1583-1586.	12.6	234
177	Unique Mutational Patterns in the Envelope Î±2 Amphipathic Helix and Acquisition of Length in gp120 Hypervariable Domains Are Associated with Resistance to Autologous Neutralization of Subtype C Human Immunodeficiency Virus Type 1. Journal of Virology, 2007, 81, 5658-5668.	3.4	92
178	Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120. Journal of Virology, 2007, 81, 4886-4891.	3.4	66
179	Capturing viral diversity for in-vitro test reagents and HIV vaccine immunogen design. Current Opinion in HIV and AIDS, 2007, 2, 183-188.	3.8	4
180	Centralized HIV-1 Envelope Immunogens and Neutralizing Antibodies. Current HIV Research, 2007, 5, 572-577.	0.5	27

#	Article	IF	Citations
181	Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine. PLoS ONE, 2007, 2, e984.	2.5	247
182	Extensive HLA class I allele promiscuity among viral CTL epitopes. European Journal of Immunology, 2007, 37, 2419-2433.	2.9	120
183	Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology, 2007, 46, 339-349.	7.3	90
184	Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nature Medicine, 2007, 13, 100-106.	30.7	400
185	Genetic Characterization of Diverse HIV-1 Strains in an Immigrant Population Living in New York City. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 399-404.	2.1	40
186	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nature Immunology, 2006, 7, 173-178.	14.5	209
187	Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology, 2006, 345, 44-55.	2.4	37
188	A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology, 2006, 353, 268-282.	2.4	176
189	Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. Journal of Virological Methods, 2006, 136, 118-125.	2.1	88
190	A jumping profile Hidden Markov Model and applications to recombination sites in HIV and HCV genomes. BMC Bioinformatics, 2006, 7, 265.	2.6	85
191	A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology, 2006, 44, 1355-1361.	7.3	105
192	jpHMM at GOBICS: a web server to detect genomic recombinations in HIV-1. Nucleic Acids Research, 2006, 34, W463-W465.	14.5	47
193	Immunoinformatics Comes of Age. PLoS Computational Biology, 2006, 2, e71.	3.2	156
194	Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa. Journal of Virology, 2006, 80, 11776-11790.	3.4	334
195	A Plea for Justice for Jailed Medical Workers. Science, 2006, 314, 924-925.	12.6	3
196	Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env Immunogen. Journal of Virology, 2006, 80, 6745-6756.	3.4	62
197	Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants. Journal of Virology, 2006, 80, 6525-6533.	3.4	87
198	Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques. Journal of Virology, 2006, 80, 999-1014.	3.4	55

#	Article	IF	Citations
199	Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control. Journal of Virology, 2006, 80, 3122-3125.	3.4	275
200	Impact of HLA-B Alleles, Epitope Binding Affinity, Functional Avidity, and Viral Coinfection on the Immunodominance of Virus-Specific CTL Responses. Journal of Immunology, 2006, 176, 4094-4101.	0.8	150
201	HLA and HIV Infection Progression: Application of the Minimum Description Length Principle to Statistical Genetics. Lecture Notes in Computer Science, 2006, , 1-12.	1.3	0
202	HIV-1 intra-subtype superinfection rates: estimates using a structured coalescent with recombination. Infection, Genetics and Evolution, 2005, 5, 85-95.	2.3	18
203	Expression and evolutionary analysis of West Nile virus (Merion Strain). Journal of NeuroVirology, 2005, 11, 544-556.	2.1	5
204	Killer cell immunoglobulinâ€like receptors (KIR) of the Africanâ€origin sabaeus monkey: evidence for recombination events in the evolution of KIR. European Journal of Immunology, 2005, 35, 922-935.	2.9	32
205	Structure of a V3-Containing HIV-1 gp120 Core. Science, 2005, 310, 1025-1028.	12.6	696
206	Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. Journal of Experimental Medicine, 2005, 201, 891-902.	8.5	220
207	Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein. Journal of Virology, 2005, 79, 1154-1163.	3.4	189
208	HLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load. Journal of Virology, 2005, 79, 10218-10225.	3.4	68
209	Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels. Journal of Virology, 2005, 79, 6528-6531.	3.4	241
210	Los Alamos Hepatitis C Immunology Database. Applied Bioinformatics, 2005, 4, 217-225.	1.6	63
211	PUBLIC HEALTH: Enhanced: A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials. Science, 2004, 303, 316-316.	12.6	123
212	Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities. Journal of Virology, 2004, 78, 2187-2200.	3.4	270
213	Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission. Science, 2004, 303, 2019-2022.	12.6	572
214	Maternal viral load and rate of disease progression among vertically HIV-1-infected children. Aids, 2004, 18, 99-108.	2.2	40
215	Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor. Journal of Virology, 2004, 78, 2790-2807.	3.4	195
216	Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature, 2004, 432, 769-775.	27.8	784

#	Article	IF	Citations
217	The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology, 2004, 321, 8-22.	2.4	72
218	Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies. Journal of Virology, 2004, 78, 13232-13252.	3.4	665
219	Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology, 2004, 14, 1229-1246.	2.5	409
220	Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Review of Vaccines, 2004, 3, S161-S168.	4.4	54
221	HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. Aids, 2004, 18, 1383-1392.	2.2	99
222	Recent Evolutionary History of Human Immunodeficiency Virus Type 1 Subtype Bâ€"Response. Journal of Molecular Evolution, 2003, 56, 643-644.	1.8	5
223	Advantage of rare HLA supertype in HIV disease progression. Nature Medicine, 2003, 9, 928-935.	30.7	311
224	Enhanced Detection of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses to Highly Variable Regions by Using Peptides Based on Autologous Virus Sequences. Journal of Virology, 2003, 77, 7330-7340.	3.4	133
225	Structure and Function of CC-Chemokine Receptor 5 Homologues Derived from Representative Primate Species and Subspecies of the Taxonomic Suborders Prosimii and Anthropoidea. Journal of Virology, 2003, 77, 12310-12318.	3.4	18
226	T Cell Responses in HIV Type 1-Infected Adolescent Minorities Share Similar Epitope Specificities with Whites Despite Significant Differences in HLA Class I Alleles. AIDS Research and Human Retroviruses, 2003, 19, 1017-1026.	1.1	18
227	Epitope Escape Mutation and Decay of Human Immunodeficiency Virus Type 1-Specific CTL Responses. Journal of Immunology, 2003, 171, 5372-5379.	0.8	68
228	Characterization and Comparison of Recombinant Simian Immunodeficiency Virus from Drill () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 4867-4880.	3.4	51
229	Cross-Reactive CD8+ T Cell Epitopes Identified in US Adolescent Minorities. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 426-438.	2.1	33
230	Genetic and Functional Analysis of Full-Length Human Immunodeficiency Virus Type 1 env Genes Derived from Brain and Blood of Patients with AIDS. Journal of Virology, 2003, 77, 12336-12345.	3.4	149
231	HIV sequence databases. AIDS Reviews, 2003, 5, 52-61.	1.0	124
232	Mother-to-Child Transmission in the United States of Subtypes D and A/G Human Immunodeficiency Virus Type 1. AIDS Research and Human Retroviruses, 2002, 18, 413-417.	1.1	9
233	Identification of a Novel Clade of Human Immunodeficiency Virus Type 1 in Democratic Republic of Congo. AIDS Research and Human Retroviruses, 2002, 18, 817-823.	1.1	30
234	Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. Aids, 2002, 16, 2275-2284.	2.2	58

#	Article	IF	Citations
235	Diversity Considerations in HIV-1 Vaccine Selection. Science, 2002, 296, 2354-2360.	12.6	731
236	Association between Maternal and Infant Class I and II HLA Alleles and of Their Concordance with the Risk of Perinatal HIV Type 1 Transmission. AIDS Research and Human Retroviruses, 2002, 18, 741-746.	1.1	70
237	Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation. Journal of Virology, 2002, 76, 8757-8768.	3.4	241
238	HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature, 2002, 420, 434-439.	27.8	321
239	The Sequential Introduction of HIV-1 Subtype B and CRF01AE in Singapore by Sexual Transmission: Accelerated V3 Region Evolution in a Subpopulation of Asian CRF01 Viruses. Virology, 2002, 304, 311-329.	2.4	21
240	HIV Sequence Sigmatires and Similarities. , 2002, , 55-72.		25
241	The KIR and CD94/NKG2 families of molecules in the rhesus monkey. Immunological Reviews, 2001, 183, 25-40.	6.0	47
242	Immune control of HIV: the obstacles of HLA and viral diversity. Nature Immunology, 2001, 2, 473-475.	14.5	153
243	Evolution and transmission of stable CTL escape mutations in HIV infection. Nature, 2001, 412, 334-338.	27.8	523
244	Evolutionary and immunological implications of contemporary HIV-1 variation. British Medical Bulletin, 2001, 58, 19-42.	6.9	423
245	Characterization of Novel Simian Immunodeficiency Viruses from Red-Capped Mangabeys from Nigeria (SIVrcmNG409 and -NG411). Journal of Virology, 2001, 75, 12014-12027.	3.4	96
246	HIV Type 1 Molecular Clones Able to Use the Bonzo/STRL-33 Coreceptor for Virus Entry. AIDS Research and Human Retroviruses, 2001, 17, 217-227.	1.1	18
247	Molecular Characterization of a Highly Divergent HIV Type 1 Isolate Obtained Early in the AIDS Epidemic from the Democratic Republic of Congo. AIDS Research and Human Retroviruses, 2001, 17, 1217-1222.	1.1	14
248	Using human immunodeficiency virus type 1 sequences to infer historical features of the acquired immune deficiency syndrome epidemic and human immunodeficiency virus evolution. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 855-866.	4.0	82
249	Search for the Origin of HIV and AIDS. Science, 2000, 289, 1140-1141.	12.6	10
250	Timing the Ancestor of the HIV-1 Pandemic Strains. Science, 2000, 288, 1789-1796.	12.6	819
251	Associations between Amino Acids in the Evolution of HIV Type 1 Protease Sequences under Indinavir Therapy. AIDS Research and Human Retroviruses, 1999, 15, 247-253.	1.1	27
252	Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy. New England Journal of Medicine, 1999, 340, 1605-1613.	27.0	782

#	Article	IF	Citations
253	A Polymorphism in the Regulatory Region of the CC-Chemokine Receptor 5 Gene Influences Perinatal Transmission of Human Immunodeficiency Virus Type 1 to African-American Infants. Journal of Virology, 1999, 73, 10264-10271.	3.4	123
254	Frequent Detection of Escape from Cytotoxic T-Lymphocyte Recognition in Perinatal Human Immunodeficiency Virus (HIV) Type 1 Transmission: the Ariel Project for the Prevention of Transmission of HIV from Mother to Infant. Journal of Virology, 1999, 73, 3975-3985.	3.4	62
255	A new classification for HIV-1. Nature, 1998, 391, 240-240.	27.8	733
256	An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature, 1998, 391, 594-597.	27.8	479
257	Comment to the Letter to the Editor. AIDS Research and Human Retroviruses, 1998, 14, 923-924.	1.1	4
258	Genetic Evaluation of Suspected Cases of Transient HIV-1 Infection of Infants. Science, 1998, 280, 1073-1077.	12.6	68
259	Limitations of a Molecular Clock Applied to Considerations of the Origin of HIV-1. Science, 1998, 280, 1868-1871.	12.6	77
260	Evaluation of Different V3 Peptides in an Enzyme Immunoassay for Specific HIV Type 1 Group O Antibody Detection. AIDS Research and Human Retroviruses, 1998, 14, 963-972.	1.1	6
261	Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant. Nature Medicine, 1997, 3, 549-552.	30.7	200
262	HIV-1 Evolution and Disease Progression. Science, 1996, 274, 1008-1011.	12.6	150
263	HIV Type 1 V3 Region Primer-Induced Antibody Suppression Is Overcome by Administration of C4-V3 Peptides as a Polyvalent Immunogen. AIDS Research and Human Retroviruses, 1995, 11, 211-221.	1.1	22
264	HIV-1 Reverse Transcriptase: A Diversity Generator and Quasispecies Regulator. Annals of the New York Academy of Sciences, 1993, 693, 65-70.	3.8	11
265	Diversity of V3 Region Sequences of Human Immunodeficiency Viruses Type 1 from the Central African Republic. AIDS Research and Human Retroviruses, 1993, 9, 997-1006.	1.1	150
266	Signature Pattern Analysis: A Method for Assessing Viral Sequence Relatedness. AIDS Research and Human Retroviruses, 1992, 8, 1549-1560.	1.1	253
267	The Emergence of Simian/Human Immunodeficiency Viruses. AIDS Research and Human Retroviruses, 1992, 8, 373-386.	1.1	238
268	HIV-1 Intrapatient Sequence Diversity in the Immunogenic V3 Region. AIDS Research and Human Retroviruses, 1992, 8, 1461-1465.	1.1	38
269	Epidemiological and Immunological Implications of the Global Variability of HIV-1. , 0, , 1-32.		5
270	Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail. SSRN Electronic Journal, 0, , .	0.4	4